© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
Latest Conference Articles
Kimberly Westrich on Incentivizing Value-Based Care in Benefit Design and Reimbursement Strategies
November 28th 2021, 2:00pm
National Alliance of Healthcare Purchaser Coalitions
Kimberly Westrich, MA, vice president of health services research at the National Pharmaceutical Council, discusses the shift to a value-based system from a fee-for-service one and how the health care system can incentivize high-value care.
Daniel Wolfson Discusses Mistrust, Quality Implications in the Health Care System
November 24th 2021, 12:00am
National Alliance of Healthcare Purchaser Coalitions
Daniel Wolfson, executive vice president and chief operating officer of the ABIM Foundation, speaks on factors influencing mistrust of the health care system and efforts to improve quality care.
Bentracimab Offers “Immediate, Sustained” Reversal of Antiplatelet Drug Ticagrelor in Nearly All Cases in REVERSE-IT
November 16th 2021, 2:40pm
American Heart Association Scientific Sessions
Bleeding is a risk with all antiplatelet drugs, whose effects pose a problem when patients need surgery or suffer a traumatic injury. A fast-acting reversal agent would make the drug safer to use.
Dr Deepak Bhatt Explains Interim Results of REVERSE-IT Trial
November 16th 2021, 1:00am
American Heart Association Scientific Sessions
Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, explains the interim findings of the REVERSE-IT trial that were presented at the 2021 AHA Scientific Sessions.
New Data Presented for Finerenone, Vericiguat, and SGLT2 Inhibitors at HF Session
November 16th 2021, 12:00am
American Heart Association Scientific Sessions
A panel Monday at the 2021 American Heart Association Scientific Sessions featured new results for several heart failure (HF) therapeutics, including finerenone and empagliflozin, as well as cost-effectiveness data for vericiguat.
Dr Derek Chew on the VICTORIA Trial and the Cost-effectiveness of Vericiguat
November 15th 2021, 11:00pm
American Heart Association Scientific Sessions
The VICTORIA study found vericiguat to be more cost-effective than placebo when using current societal benchmarks for health care value in the United States. Derek Chew, MD, now an assistant professor at the University of Calgary, conducted economic evaluations for the VICTORIA trial while with the Duke Clinical Research Institute. Results were presented at the 2021 AHA Scientific Sessions. Here, he explains why vericiguat is more cost-effective for patients with heart failure with reduced ejection fraction.
Teprotumumab Benefits Patients With Mild Inflammation and Real-world Adherence Remains High
November 15th 2021, 8:45pm
AAO: American Academy of Ophthalmology
Posters presented at the American Academy of Ophthalmology 2021 annual meeting showed that even patients with mild inflammation with their thyroid eye disease benefitted from teprotumumab and that real-world adherence was consistent with the pivotal clinical trials.
Teprotumumab, Enhanced Monofocal IOLs Among Hot Topics at AAO 2021
November 15th 2021, 6:35pm
AAO: American Academy of Ophthalmology
Among many presentations during a hot topics session at the American Academy of Ophthalmology 2021 annual meeting, speakers discussed the first FDA approved therapy for thyroid eye disease and the latest in enhanced monofocal intraocular lenses (IOLs).
Dr David Ramsey Describes the Impact of Telehealth on Completed Eye Examinations for Diabetic Retinopathy
November 15th 2021, 5:49pm
AAO: American Academy of Ophthalmology
David Ramsey, MD, PhD, MPH, explains findings from a study on telehealth use among patients with diabetes in Massachusetts.
Patient Voices Highlight Urgency of Achieving Health Equity During AHA Session
November 15th 2021, 3:48am
American Heart Association Scientific Sessions
A wide-ranging discussion sought to bring greater urgency to achieving health equity during the 2021 American Heart Association (AHA) Scientific Sessions.